Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.63 |
| ▸ | RARB | P10826 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825340 | 0.94 | RARB (0.71) | RARARARBMCL1MAOBPTPN11 | |
| SCHEMBL1583118 | 0.89 | RARB (0.66) | RARARARBMCL1PTPN11 | |
| SCHEMBL7821266 | 0.89 | RARB (0.66) | RARARARBMCL1PTPN11 | |
| SCHEMBL7814595 | 0.89 | RARB (0.66) | RARARARBMCL1PTPN11 | |
| SCHEMBL7824715 | 0.89 | RARB (0.66) | RARARARBMCL1PTPN11 | |
| SCHEMBL9626748 | 0.89 | RARB (0.66) | RARARARBMCL1PTPN11 | |
| Hydrochloric Acid SCHEMBL9626908 | 0.88 | RARB (0.64) | RARARARBMCL1PTPN11 | |
| Hydrochloric Acid SCHEMBL9650215 | 0.88 | RARB (0.64) | RARARARBMCL1PTPN11 | |
| SCHEMBL13366264 | 0.87 | RARA (0.55) | RARARARBMAOBKAT6AMAOA | |
| SCHEMBL5647136 | 0.86 | RARA (0.66) | RARARARBMCL1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001020995-A9 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | UNIV WASHINGTON (US) | 2002-11-14 | — | — | WO | claimed |
| WO-2001020995-A1 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | WASHINGTON UNIVERSITY (US) | 2001-03-29 | — | — | WO | claimed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | claimed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| CN-1111167-C | 3 beta-hydroxy-5-cholenic acid ester derivant, synthesis process and use thereof | SHANGHAI INST ORGANIC CHEM (CN) | 2003-06-11 | — | — | CN | disclosed |
| CN-1111169-C | Sterol derivative, synthesis method and its application | SHANGHAI INST ORGANIC CHEM (CN) | 2003-06-11 | — | — | CN | disclosed |
| WO-2001020995-A9 | COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF | UNIV WASHINGTON (US) | 2002-11-14 | — | — | WO | disclosed |
| CN-1263104-A | Sterol derivative, synthesis method and its application | SHANGHAI INST ORGANIC CHEM (CN) | 2000-08-16 | — | — | CN | disclosed |
| CN-1257077-A | 3 beta-hydroxy-5-cholenic acid ester derivant, synthesis process and use thereof | SHANGHAI INST ORGANIC CHEM (CN) | 2000-06-21 | — | — | CN | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5998660-A | BY-PRODUCT INHIBITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0855996-A1 | OXIDATION OF ALDEHYDES TO CARBOXYLIC ACIDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5739352-A | Process for preparing carboxylic acids | UNITED CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997014668-A9 | OXIDATION OF ALDEHYDES TO CARBOXYLIC ACIDS | — | 1997-08-07 | — | — | WO | disclosed |
| WO-1997014668-A1 | OXIDATION OF ALDEHYDES TO CARBOXYLIC ACIDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-04-24 | — | — | WO | disclosed |
| US-4020059-A | Process for preparing tertiary amines | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JA) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | RARA 3509/4885RARB 2930/4885KMT2A 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.